Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
IPO Year: 1991
Exchange: NYSE
Website: haemonetics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/7/2025 | $95.00 → $68.00 | Neutral → Underperform | BofA Securities |
| 12/6/2024 | $116.00 | Overweight | Analyst |
| 11/8/2024 | $120.00 | Outperform → Strong Buy | Raymond James |
| 9/13/2024 | $116.00 | Buy | CL King |
| 9/11/2024 | $85.00 | Neutral | BofA Securities |
| 9/10/2024 | $112.00 | Buy | BTIG Research |
| 6/12/2024 | $112.00 | Hold → Buy | Needham |
| 10/13/2022 | $90.00 | Buy | Mizuho |
| 2/9/2022 | $70.00 → $66.00 | Outperform | Raymond James |
| 1/27/2022 | Buy → Hold | Needham |
BOSTON, May 30, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:40 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.webcasts.com/starthere.jsp?ei=1721260&tp_key=3096fdc651&tp_special=8 A replay of the recorded webcast will become accessible 12 hours after the event and will be availab
Financial release accessible online BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BI8b22e12b2
First fully absorbable, sutureless closure system designed for large-bore procedures aims to improve procedural efficiency and patient outcomes in structural heart interventions Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced European CE mark approval of the PerQseal® Elite vascular closure system, a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer. Leveraging Vivasure's PerQseal technology, the PerQseal Elite vascular closure system is designed exclusively for sutureless and fully absorbable large-bore closure follow
BOSTON, March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025. The call can be accessed via teleconference at: Q4 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call.
Frank Chan joins Haemonetics as Executive Vice President, Chief Operating Officer; Roy Galvin named Executive Vice President, Chief Commercial Officer BOSTON, March 3, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced updates to its Executive Leadership team. Frank Chan, Ph.D. will join Haemonetics as Executive Vice President, Chief Operating Officer on April 7, 2025, and Roy Galvin has been appointed as the company's Executive Vice President, Chief Commercial Officer effective immediately.
BOSTON, Feb. 24, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 at 2:50 p.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://wsw.com/webcast/rj131/hae/1437678. A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics'
Financial release accessible online BOSTON, Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 6, 2025. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BIda08929a4d56464
BOSTON, Jan. 14, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has completed the previously announced sale of its whole blood assets to GVS, S.p.A ("GVS"), one of the world's leading manufacturers of filter solutions for applications in the healthcare and life sciences sectors. In connection with the closing of this transaction, GVS has acquired Haemonetics' portfolio of proprietary whole blood collection, processing and filtration solutions, along with Haemonetics' manufacturing facility in Covina, California where certain of these prod
BOSTON, Jan. 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish third quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, February 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 6, 2025. The call can be accessed via teleconference at: Q3 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the cal
BOSTON, Jan. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 5:15 pm Pacific Time. The public may access Mr. Simon's presentation live via audio webcast at: https://jpmorgan.metameetings.net/events/healthcare25/sessions/58190-haemonetics-corporation/webcast?gpu_only=true&kiosk=true The live webcast can also be accessed under the Events & Presentations section of Haemonetics' Investor Relations website. The
SD - HAEMONETICS CORP (0000313143) (Filer)
10-K - HAEMONETICS CORP (0000313143) (Filer)
SCHEDULE 13G/A - HAEMONETICS CORP (0000313143) (Subject)
8-K - HAEMONETICS CORP (0000313143) (Filer)
8-K - HAEMONETICS CORP (0000313143) (Filer)
10-Q - HAEMONETICS CORP (0000313143) (Filer)
8-K - HAEMONETICS CORP (0000313143) (Filer)
8-K - HAEMONETICS CORP (0000313143) (Filer)
8-K - HAEMONETICS CORP (0000313143) (Filer)
8-K - HAEMONETICS CORP (0000313143) (Filer)
SC 13G - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ
BOSTON, Oct. 4, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced the appointment of Roy Galvin as President, Global Plasma and Blood Center, effective October 10, 2022. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer. As President of Haemonetics' Global Plasma and Blood Center business units, Galvin will have responsibility for driving the Company's transformational growth objectives and advancing the
BOSTON, March 21, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) today announced that James C. D'Arecca will join the Company as Executive Vice President, Chief Financial Officer, effective April 11, 2022. He will report directly to Chris Simon, Haemonetics' President and Chief Executive Officer. In this role, D'Arecca will oversee the Company's treasury, controllership and accounting, investor relations, tax, information technology, and financial planning and analysis functions. He succeeds William P. Burke, who last year shared his decision to retire as the Company'
Financial release accessible online BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BI8b22e12b2
BOSTON, March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025. The call can be accessed via teleconference at: Q4 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call.
Financial release accessible online BOSTON, Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 6, 2025. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BIda08929a4d56464
BOSTON, Jan. 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish third quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, February 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 6, 2025. The call can be accessed via teleconference at: Q3 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the cal
Financial release accessible online BOSTON, Nov. 7, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its second quarter fiscal year 2025, which ended September 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 7, 2024. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BI3c9f473811f94
BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 7, 2024. The call can be accessed via teleconference at: Q2 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the ca
Financial release accessible online BOSTON, Aug. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal year 2025, which ended June 29, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 8, 2024. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BI5ac87cebabbb4a7aaaad3
BOSTON, July 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, August 8, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 8, 2024. The call can be accessed via teleconference at: Q1 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. W
Financial release accessible online BOSTON, May 9, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2024, which ended March 30, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 9, 2024. The conference call and webcast can be accessed with the following information: Teleconference link:https://register.vevent.com/register/BI7654787bc47144b39cb1
BOSTON, April 10, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2024 financial results at 6:00 am ET on Thursday, May 9, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 9, 2024. The call can be accessed via teleconference at: Q4 2024 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call.
BofA Securities downgraded Haemonetics from Neutral to Underperform and set a new price target of $68.00 from $95.00 previously
Analyst initiated coverage of Haemonetics with a rating of Overweight and set a new price target of $116.00
Raymond James upgraded Haemonetics from Outperform to Strong Buy and set a new price target of $120.00
CL King initiated coverage of Haemonetics with a rating of Buy and set a new price target of $116.00
BofA Securities initiated coverage of Haemonetics with a rating of Neutral and set a new price target of $85.00
BTIG Research initiated coverage of Haemonetics with a rating of Buy and set a new price target of $112.00
Needham upgraded Haemonetics from Hold to Buy and set a new price target of $112.00
Mizuho initiated coverage of Haemonetics with a rating of Buy and set a new price target of $90.00
Raymond James reiterated coverage of Haemonetics with a rating of Outperform and set a new price target of $66.00 from $70.00 previously
Needham downgraded Haemonetics from Buy to Hold
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)